ClinicalTrials.gg
Active, not recruitingNCT06616194Updated Oct 23, 2026

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

A Phase 3 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Active, not recruiting at 102 sites in 12 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Updated Oct 23, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
636
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Planned enrollment
16th of 32
636 · median 618
Started
2024
with 1 other
Phase 3
14 of 32
5 open now
Primary completion
2030-02
later than 13 of 14 live
Registered
21st of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 16th largest by planned enrollment, is one of 2 that started in 2024, is one of 14 in phase 3, reaches primary completion later than 13 of the 14 other live ones, and was the 21st registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks.

Rimegepant is a tablet that disintegrates when you put it on or under your tongue.

The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours

In the 1st part of the study approximately half of the participants will receive a rimegepant tablet every other day, and approximately half of the participants will receive an inactive oral tablet (that looks the same as the rimegepant tablet) every other day.

Participant experiences when they are taking the study medicine will be compared to when they are taking the inactive tablet. This will help to determine if the study medicine is safe and effective. The 1st phase of the study will last 3 months.

In the 2nd part of the study all the participants who stay on study will receive rimegepant tablet every other day. This 2nd phase of the study will last 1 year. This will help determine if the study medicine is safe when taken for a long period.

Those who will participate in both phases will have up to 19 visits at the study clinic, about one every 4 weeks (this may vary from 2 to 8 weeks interval during the study). Home health visits may occur as well. A health check and blood sample will be conducted at the study clinic visits. Participants will have to complete a daily diary to record the migraine attacks.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Chronic migraine
  • adolescents
  • rimegepant,
  • cgrp
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 6 month history of migraine (with or without aura)
  • 15 or more headache days/month
  • 8 or more migraine days/month
  • Migraine lasting 4-72 hours if untreated

Exclusion criteria

Exclusion Criteria:

  • Unrelenting headache
  • Current psychiatric condition uncontrolled or untreated
  • History of suicidal behavior or the subject is at risk of self-harm
  • History of alcohol abuse and/or illicit drug use
  • History of severe drug allergy
  • Use of more than one medication for migraine prevention/prophylaxis
  • Participation in another clinical trial at the same time
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
636 participants (estimated)

Study arms

  • Experimental
    Rimegepant

    Experimental medicine under study

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    A placebo does not have any medicine in it but looks just like the medicine being studied.

    Drug: Placebo

Interventions

  • Rimegepant 75 mg orally disintegrating tablets

  • DrugPlacebo

    Matching placebo oral disintegrating tablets

06

What researchers measure

Primary outcomes

  1. Number of migraine days per month

    Efficacy of rimegepant relative to placebo, measured as mean change from the baseline in the number of migraine days per month

    Time frame: 12 Weeks

Secondary outcomes

  1. Efficacy of rimegepant relative to placebo measured as the mean change from baseline in the number of acute migraine-specific medication days per month

    Change in the use of acute migraine-specific medication days per month

    Time frame: 12 Weeks

  2. Efficacy of rimegepant relative to placebo measured the mean change from baseline in the number of moderate or severe headache days per month

    Change in headache days per month

    Time frame: 12 Weeks

  3. Efficacy of rimegepant relative to placebo measured as the percentage of participants with at least 50% reduction from baseline in number of moderate or severe migraine days per month

    Change in moderate or severe migraine days per month

    Time frame: 12 weeks

  4. Efficacy of rimegepant relative to placebo measured as the mean change from baseline in the Pediatric Quality of Life (PedsQL™) total score

    Change in the Quality of Life

    Time frame: 12 Weeks

  5. Efficacy of rimegepant relative to placebo measure as the mean change from baseline in the number of acute headache medication days per month, and acute migraine-specific medication days per month

    Change in headache and migraine rescue medication(s) used

    Time frame: 12 Weeks

  6. Safety of rimegepant relative to placebo, and safety of rimegepant given for a long period of time measured as the number and percentage of participants with adverse event by severity and overall

    Safety and tolerability of the study drug

    Time frame: Up to 15 months

  7. Safety of rimegepant relative to placebo, and safety of rimegepant given for long period of time measured as the number and percentage of participants with liver-related adverse event and action taken

    Safety monitoring of adverse events of special interest

    Time frame: Up to 15 Months

  8. Efficacy of rimegepant relative to placebo measured as mean change from baseline in the PedMIDAS total score

    Change in the Quality of Life

    Time frame: 12 Weeks

07

Study locations

102 sites

Showing the first 100 of 102 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Shin L, Mentz O, Gelfand AA, de Prado BM, Shapiro H, Oh A, Onifade OO, Saunders J, Raj N, Szperka CL. Gepants for headache prevention in children and adolescents: A multicenter chart review study. Headache. 2026 Jan;66(1):239-248. doi: 10.1111/head.15087. Epub 2025 Nov 14. PubMed 41235617 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Feb 2030, 63 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 63 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Aug 2028 → Feb 2030 and completion Oct 2029 → Apr 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 27, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Feb 26, 2030was Aug 2028
CompletionEst.
Apr 22, 2031was Oct 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Headlands-EI Paso · El Paso, United States
Show 1 removed
  • Headlands Research-El Paso · El Paso, United States
Oct 23, 2026
Primary completion
Aug 19, 2028→Feb 26, 2030
Oct 23, 2026
Study completion
Oct 13, 2029→Apr 22, 2031
Oct 23, 2026
Enrollment
200→636
Oct 23, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedEfficacy of rimegepant relative to placebo measured the mean change from baseline in the number of moderate or severe headache days per monthTime frame: 12 Weeks
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added, 1 site removed
    Show site
    • Headlands-EI Paso · El Paso, United States
    Show 1 removed
    • Headlands Research-El Paso · El Paso, United States
    Primary completion Aug 19, 2028→Feb 26, 2030
    Study completion Oct 13, 2029→Apr 22, 2031
    Enrollment 200→636
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedEfficacy of rimegepant relative to placebo measured the mean change from baseline in the number of moderate or severe headache days per monthTime frame: 12 Weeks
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06616194
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 27, 2024
Start date
Nov 15, 2024
Primary completion
Feb 26, 2030 (estimated)
Completion
Apr 22, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion